Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7

Adachi, Katsuyuki; Kawana, Kei; Yokoyama, Terufumi; Fujii, Tomoyuki; Tomio, Ayako; Miura, Shigeki; Tomio, Kensuke; Kojima, Satoko; Oda, Katsutoshi; Sewaki, Tomomitsu; Yasugi, Toshiharu; Kozuma, Shiro; Taketani, Yuji

doi:10.1016/j.vaccine.2010.02.005

Cited by 84 publications

(58 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, HA 1 is an important target for vaccine development. Lactobacillus is widely used as a live vaccine vehicle against various microbes (1,7,35). Accordingly, we constructed a recombinant plasmid, pLEM415-PHA 1 , and recombinant lactobacillus strains, LA4356-pH and DLD17-pH, that produce the HPAI virus protective antigen HA 1 .…”

Section: Discussionmentioning

confidence: 99%

Mucosal and Systemic Immune Responses Induced by Recombinant Lactobacillus spp. Expressing the Hemagglutinin of the Avian Influenza Virus H5N1

Wang

Gao

et al. 2012

Clin Vaccine Immunol

View full text Add to dashboard Cite

To develop a safe, effective, and convenient vaccine for the prevention of highly pathogenic avian influenza (HPAI), we have successfully constructed two recombinant lactobacillus strains (LA4356-pH and DLD17-pH) that express the foreign HPAI virus protein hemagglutinin 1 (HA 1 ). The mucosal and systemic immune responses triggered by these two recombinant lactobacilli following oral administration to BALB/c mice were evaluated. The results showed that both LA4356-pH and DLD17-pH could significantly increase the specific anti-HA 1 IgA antibody level in the mucosa and the anti-HA 1 IgG level in serum, as well as stimulating the splenic lymphocyte proliferative reaction through increased expression of interleukin-4 (IL-4). Compared with LA4356-pH, DLD17-pH was more effective at inducing systemic and mucosal immune responses, with higher anti-HA 1 -specific IgA and IgG levels. Therefore, DLD17-pH could be a promising oral vaccine candidate against HPAI. Highly pathogenic avian influenza (HPAI) virus (H5N1) is a threat to the world's poultry industry. As a zoonotic agent, this virus also has the potential to cause a human pandemic (29). Current vaccination (by intramuscular immunization) against HPAI has succeeded in reducing morbidity and mortality in poultry. However, the intense stress caused by injection could hamper the animal's growth (34). Thus, many investigators are pursuing more convenient and economical avenues for construction of new vaccine candidates, such as recombinant subunit vaccines using baculovirus (28), plasmid DNA (3), or replication-incompetent adenovirus (rAd) (26, 27) vectors. The H5N1 strain can infect animals through their respiratory and intestinal tracts (10). Because there are many mucosa-associated lymphoid tissues underneath the epithelia of the respiratory and intestinal tracts, protective HPAI virus antigens may induce an effective mucosal immune response to prevent the invasion of HPAI virus if they can be transported easily to these tissues. Thus, developing mucosal vaccine candidates based on these considerations is a feasible strategy.Mucosal vaccines, which are administered mainly orally or intranasally, cause less stress in the animal and have been the subject of growing interest due to the advantages that they offer over conventional parenteral vaccines. The biggest advantage is the stimulation of mucosal immune responses (15,24). Lactobacillus is a genus of Gram-positive facultative anaerobic or microaerophilic rod-shaped bacteria. These beneficial bacteria normally live in the digestive, urinary, and genital systems without causing disease. Their abilities to transit through the stomach intact and to associate closely with the intestinal epithelium, combined with their immunomodulatory properties, have made Lactobacillus spp. attractive candidates as live vehicles for the delivery of immunogens to the intestinal mucosa (6, 12). It was recently shown that specific Lactobacillus species can induce inflammatory responses against infection, increase IgA production, activate mo...

show abstract

Section: Discussionmentioning

confidence: 99%

Mucosal and Systemic Immune Responses Induced by Recombinant Lactobacillus spp. Expressing the Hemagglutinin of the Avian Influenza Virus H5N1

Wang

Gao

et al. 2012

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…Intravaginal immunization with live vectors such as live Salmonella enterica serovar Typhimurium or Lactococcus lactis expressing HPV antigens, or HPV pseudovirus as a vector that transiently expresses respiratory syncytial virus antigens, induced strong serum and vaginal antibody and CD8 + T cell responses (Bermudez-Humarah et al, 2005;Manuri et al, 2007Echchannaoui et al, 2008Adachi et al, 2010;Cuburu et al, 2012). A comparison of systemic (subcutaneous) and mucosal (intranasal or intravaginal) immunization routes with HPV-16 E7 polypeptide vaccine in a murine model demonstrated the superiority of the systemic route in the prevention of tumor growth and CD8 + T-cell-mediated regression of established genital tumors (Decrausaz et al, 2011).…”

Section: Human Papillomavirusmentioning

confidence: 99%

Immunity to Sexually Transmitted Infections

et al. 2015

View full text Add to dashboard Cite

“…In addition, this yeast oral vaccine can be prepared rapidly because, unlike proteins produced in E. coli, it does not require a complicated purification step, and mutations can be easily generated because the plasmid DNA is easy to be manipulated. Although only a yeast system for molecular display is described here, bacterial systems can also be used [44,45].…”

Section: A Convenient Tool For Preparation Of Antigenic Proteinsmentioning

confidence: 99%

Combining Proteomic Strategies and Molecular Display Technology for Development of Vaccines against Candida albicans

Karasaki¹

2014

J Proteomics Bioinform

View full text Add to dashboard Cite

Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7

Cited by 84 publications

References 42 publications

Mucosal and Systemic Immune Responses Induced by Recombinant Lactobacillus spp. Expressing the Hemagglutinin of the Avian Influenza Virus H5N1

Mucosal and Systemic Immune Responses Induced by Recombinant Lactobacillus spp. Expressing the Hemagglutinin of the Avian Influenza Virus H5N1

Immunity to Sexually Transmitted Infections

Combining Proteomic Strategies and Molecular Display Technology for Development of Vaccines against Candida albicans

Contact Info

Product

Resources

About